Document Type : Research Articles
Research Center for Genetic Engineering, National Research and Innovation Agency (BRIN), Bogor, 16911, West Java, Indonesia.
Present address: The International Institute of Molecular Mechanisms and Machines, Polish Academy of Sciences, Warsaw, Poland.
Research Center for Applied Zoology, National Research and Innovation Agency (BRIN), Bogor, 16911, West Java, Indonesia.
Research Center for Vaccine and Drug, National Research and Innovation Agency (BRIN), Bogor, 16911, West Java, Indonesia.
Background: Human Papillomavirus type 52 (HPV 52) is considered one of the threatening HPV types inducing cervical cancer worldwide. This study was conducted to address strategies of an effective vaccine against cervical cancer using computational approaches immuno-informatics and molecular docking. Methods: Major capsid protein L1 and L2 HPV 52 (L1 and L2 HPV 52) sequences were investigated by multiple analyses including B and T cell epitope, toxicity, allergenicity, Immunogenicity, epitope conservancy, population coverage, and molecular docking. Results: L1 and L2 HPV 52 showed a conserved sequence among amino acid levels. Q307K, S383D/N, and D473E are found as major mutations in L1, while mutations in L2 are S122T, Q247H, L247S, and E365D. Multiple epitopes were identified and elicited strong immune responses against cross types of HPV in various HLA populations. To enhance vaccine effectiveness that allows having cross-protection over HPV types, N terminus HPV L2 was analyzed suggesting multi-candidates chimeric L1/L2 vaccine design. Conclusion: This study shed a light on a useful pipeline with robust analysis for effective vaccine production.